| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2023 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 83,039 | $528.50 | $43,886,429.76 | - | +11.9% | +68.8% | |
| Aug 11, 2023 | AMRX Amneal Pharmaceuticals, Inc. | Boyer Andrew S | Executive Vice President | Sell | 29,302 | $4.13 | $120,920.56 | -10.7% | +4.5% | +92.7% | |
| Aug 11, 2023 | AVDL Avadel Pharmaceuticals Plc | McCamish Mark Anthony | Director | Sell | 28,975 | $14.93 | $432,614.14 | -16.9% | -23.7% | +6.6% | |
| Aug 11, 2023 | LNTH Lantheus Holdings, Inc. | Niedzwiecki Daniel54 | See Remarks | Sell | 4,297 | $67.93 | $291,895.21 | -6.1% | -10.0% | +41.1% | |
| Aug 11, 2023 | LLY Eli Lilly & Co | Eli Lilly & Co | 10% Owner | Buy | 1,718,493 | $14.92 | $25,639,915.56 | -100.0% | +11.9% | +68.8% | |
| Aug 11, 2023 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | CEO | Sell | 10,950 | $68.58 | $750,981.47 | -1.6% | -10.0% | +41.1% | |
| Aug 10, 2023 | AVDL Avadel Pharmaceuticals Plc | Divis Gregory J71 | Chief Executive Officer | Buy | 10,000 | $13.20 | $131,997.00 | +6.7% | -13.5% | +15.5% | |
| Aug 10, 2023 | AVDL Avadel Pharmaceuticals Plc | Glass Geoffrey Michael70 | Director | Buy | 14,000 | $13.40 | $187,600.00 | +31.1% | -13.5% | +15.5% | |
| Aug 10, 2023 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 3,000 | $528.14 | $1,584,405.00 | - | +18.8% | +71.0% | |
| Aug 9, 2023 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 123,961 | $528.83 | $65,554,314.24 | - | +14.0% | +60.6% | |
| Aug 9, 2023 | ZTS Zoetis Inc. | Polzer Robert J59 | Executive Vice President | Sell | 1,179 | $189.94 | $223,939.26 | -33.4% | -11.7% | -0.6% | |
| Aug 8, 2023 | DVAX Dynavax Technologies Corp | Hack Andrew A. F.62 | Director | Sell | 1,500,000 | $14.39 | $21,585,000.00 | -62.1% | -9.3% | -27.8% | |
| Aug 8, 2023 | DVAX Dynavax Technologies Corp | Novack David F73 | President &COO | Sell | 40,000 | $14.87 | $594,900.00 | -40.2% | -9.3% | -27.8% | |
| Aug 8, 2023 | DVAX Dynavax Technologies Corp | Janssen Robert71 | SVP And CMO | Sell | 2,600 | $15.05 | $39,130.00 | -5.0% | -9.3% | -27.8% | |
| Aug 8, 2023 | HIMS Hims & Hers Health, Inc. | Dudum Andrew48 | Chief Executive Officer | Sell | 6,900 | $9.04 | $62,381.52 | -100% | -15.6% | +115.6% | |
| Aug 8, 2023 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 204,409 | $523.74 | $107,056,404.79 | - | +14.1% | +48.0% | |
| Aug 8, 2023 | PBH Prestige Consumer Healthcare Inc. | Lombardi Ronald M.52 | Chief Executive Officer | Sell | 32,800 | $65.57 | $2,150,536.38 | -2.9% | -7.1% | +5.6% | |
| Aug 7, 2023 | HIMS Hims & Hers Health, Inc. | Baird Melissa | Chief Operating Officer | Sell | 9,133 | $8.00 | $73,052.13 | -2.1% | -20.5% | +113.7% | |
| Aug 7, 2023 | DVAX Dynavax Technologies Corp | Burgess Justin60 | Chief Accounting Officer | Sell | 8,061 | $14.55 | $117,247.25 | -100% | -8.4% | -31.9% | |
| Aug 7, 2023 | MIRA Mira Pharmaceuticals, Inc. | Cappy George | - | Buy | 119,048 | $7.00 | $833,336.00 | +4.3% | -77.3% | -63.5% | |
| Aug 7, 2023 | TEVA Teva Pharmaceutical Industries Ltd | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | Sell | 35,125 | $9.73 | $341,889.19 | -26.2% | -6.0% | +75.6% | |
| Aug 4, 2023 | TEVA Teva Pharmaceutical Industries Ltd | Weiss Amir | Chief Accounting Officer | Sell | 1,981 | $9.92 | $19,657.57 | -4.5% | -10.0% | +74.1% | |
| Aug 4, 2023 | HIMS Hims & Hers Health, Inc. | Baird Melissa | Chief Operating Officer | Sell | 18,266 | $8.22 | $150,200.40 | -2.0% | -25.4% | +115.7% | |
| Aug 3, 2023 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $236.25 | $1,417,470.05 | -2.2% | -3.4% | +41.3% | |
| Aug 3, 2023 | MRK Merck & Co., Inc. | Mizell Steven52 | EVP, Chief Hr Officer | Sell | 4,500 | $105.49 | $474,700.95 | -14.2% | -2.1% | +11.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.